Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 12 recruiting now early-phase tilt

Dyslipidemias: early-phase trial registry

12 of 29 indexed Dyslipidemias trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #552 of 28,707 conditions by registered trial count.

29 US clinical trials · 12 currently recruiting · #552 of 28,707 conditions by registered trial count

Dyslipidemias: 29 US clinical trials tracked, 12 recruiting.

Dyslipidemias is the subject of 29 registered US clinical trials on ClinicalTrials.gov, 12 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is University of Hawaii, running 2 of these trials.

Enrollment posture brief

Registry condition dyslipidemias

OPEN 12 | RECR 41% | LATE 2 | EARLY 9 | RANK #552 | SPON 2

Nearest open-share peer: Exercise (41% recruiting · 58 trials)

Advanced Breast Cancer62.1%Amyloidosis51.7%Dyslipidemias (this)41%Arthritis, Rheumatoid17.2%Adult Acute Myeloid Leukemia0%
Open-enrollment share among volume-matched conditions near Dyslipidemias

Dyslipidemias lists 12 open slots (41% of 29 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Dyslipidemias on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Dyslipidemias recruits in line with its size-band peers.

    12 of 29 indexed trials (41.4%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Dyslipidemias trials is spread across many organizations.

    University of Hawaii accounts for 2 of 29 trials (6.9%). 26 distinct sponsors appear on at least one study for this condition label.

  3. Typical Dyslipidemias enrolment sits around 85 participants.

    Median target enrolment is 85 among the 29 trials that report a genuine target (sentinel values excluded). 16 of those (55.2%) plan for fewer than 100 participants.

  4. Dyslipidemias research is mostly interventional.

    25 interventional and 4 observational studies make up this index (86.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 14Phase 25Phase 31Phase 41

Open and recent trials

29 total, page 1 of 1

RECRUITING NA 1,780 participants

'Ai Pono Cooking Demonstrations

University of Hawaii

NCT06526650

RECRUITING 650 participants

Military Health and Nutrition Examination Study

Pennington Biomedical Research Center

NCT06380322

RECRUITING NA 400 participants

Randomized Controlled Trial of Alert-Based Computerized Decision Support for Patients With Peripheral Artery Disease Not Prescribed Lipid-Lowering Therapy

Brigham and Women's Hospital

NCT06300450

RECRUITING 300 participants

Gut Microbiota in Metabolic Surgery

Vanderbilt University Medical Center

NCT05000996

RECRUITING NA 210 participants

PILI 'Āina Household

University of Hawaii

NCT06526273

RECRUITING 150 participants

Addressing Barriers to Achieving Cardiometabolic Disorders Prevention and Treatment Goals for PLWH in the SE US

Duke University

NCT05129345

RECRUITING NA 150 participants

Dietary Supplementation on Body Fat Composition

Brightseed

NCT06296251

RECRUITING Early Phase 1 130 participants

Evaluation of Milk Polar Lipids in Dyslipidemic Adults With Abdominal Obesity

University of Connecticut

NCT05700916

RECRUITING Phase 2 121 participants

Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)

Priscilla Hsue, MD

NCT05488431

RECRUITING NA 80 participants

Dose Response Effects of Pecan Consumption

University of Georgia

NCT05949879

RECRUITING NA 80 participants

Cottonseed Oil Dose Response

University of Georgia

NCT05686954

RECRUITING Phase 2 69 participants

Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels

NewAmsterdam Pharma

NCT06496243

ACTIVE NOT RECRUITING NA 1,029 participants

The PIVOT Trial: Project on EHR-Integrated Lifestyle Interventions for Adults Aged Fifty and Older

University of Illinois at Chicago

NCT05654142

ACTIVE NOT RECRUITING Phase 2 90 participants

Causal Mechanisms in Adolescent Arterial Stiffness

Baylor College of Medicine

NCT04128969

ACTIVE NOT RECRUITING NA 31 participants

The Effects of Fresh Mango Consumption on Cardiometabolic Outcomes in Free-living Individuals With Prediabetes

Loma Linda University

NCT06159543

COMPLETED Phase 2 418 participants

Study of ARO-APOC3 in Adults With Dyslipidemia

Arrowhead Pharmaceuticals

NCT05413135

COMPLETED NA 210 participants

Medically Tailored Groceries and Food Resource Coaching

University of Texas Southwestern Medical Center

NCT06242808

COMPLETED Phase 3 118 participants

Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)

University of California, San Francisco

NCT03207945

COMPLETED NA 85 participants

A Quality Improvement Process to Support Delivery of Cardiovascular Care in Community Mental Health Organizations

Johns Hopkins University

NCT04696653

COMPLETED NA 71 participants

Evaluation of a Lifestyle Medicine Practice

Ohio University

NCT03739034

COMPLETED Phase 1 70 participants

Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)

Silence Therapeutics

NCT04606602

COMPLETED Phase 1 60 participants

A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia

Eli Lilly and Company

NCT02714569

COMPLETED Phase 1 48 participants

A Study of LY3475766 in Healthy Participants

Eli Lilly and Company

NCT04052594

COMPLETED NA 40 participants

Developing an Adaptive Lifestyle Intervention Program in Family Medicine Clinics

University of Alabama at Birmingham

NCT04392284

COMPLETED NA 36 participants

12 Weeks of Resistance Band Exercise Impacts on Metabolic Syndrome Progression in Postmenopausal Women

Pusan National University

NCT04014686

COMPLETED NA 35 participants

Zinc Supplement Before or With Food in Generally Healthy Men

UCSF Benioff Children's Hospital Oakland

NCT03619421

COMPLETED Phase 4 26 participants

Effects of Psyllium on Niacin Tolerability

VA Greater Los Angeles Healthcare System

NCT03370848

COMPLETED Phase 2 16 participants

Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia

Catabasis Pharmaceuticals

NCT01968720

COMPLETED 16 participants

Production of Free Fatty Acids From Blood Triglycerides

Mayo Clinic

NCT00911482

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 5
Phase 3 1
Phase 4 1

Named interventions

Most-linked intervention names on Dyslipidemias records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
3 trials
Placebo Other
2 trials
CONTROL Other
2 trials
ARO-APOC3 Drug
1 trials
Placebo - SC Drug
1 trials
Placebo - IV Drug
1 trials
LY3475766 - SC Drug
1 trials
LY3475766 - IV Drug
1 trials

US sites by state

Facility locations filed on Dyslipidemias trials. A trial with sites in several states counts in each.

California 7 trials
Florida 5 trials
Texas 4 trials
Ohio 3 trials
Georgia 3 trials
Pennsylvania 2 trials
Nebraska 2 trials
North Carolina 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Dyslipidemias page

29 registered trials, 12 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Dyslipidemias condition card totals 29 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.